Skip to main content

Table 3 Difference between FEV1 values at baseline (T0) and after 12 weeks (T1) in groups A and B

From: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma

 

Group A

Group B

DIfference Group B – Group A

 

T0

T1

Difference T1 – T0

p

T0

T1

Difference T1 – T0

p-value

Difference T1-T0

p-value

FEV1 (L) mean (±SE)

2.52 (±0.13)

2.62 (±0.12)

0.10

0.519

2.51 (±0.12)

2.72 (±0.13)

0.21

0.229

0.11

0.007

FEV1 (%), mean (±SE)

82.40 (±1.63)

87.08 (±1.58)

4.68

0.043

81.93 (±2.00)

89.50 (±2.64)

7.57

0.009

2.89

0.04

  1. T0 =at baseline, before Beclomethasone dipropionate/Formoterol and Fluticasone furoate/Vilanterol treatment
  2. T1 = after 12 weeks of Beclomethasone dipropionate/Formoterol and Fluticasone furoate/Vilanterol treatment
  3. Forced expiratory volume in 1 s, litres, FEV1 (L)
  4. Forced expiratory volume in 1 s, predicted values, FEV1(%)
  5. [95 % CI, confidence interval]
  6. p refers to Wilcoxon rank-sum test
  7. Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
  8. Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day
Back to article page

Multidisciplinary Respiratory Medicine

ISSN: 2049-6958

Contact us